I think it's very likely just a generic company "getting in line" to be first for exclusivity when the patent finally expires.
Since Hatch-Waxman was modified in 2003, this ploy does not work unless it induces a favorable settlement with the branded-drug company (BMY in this instance).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.